Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Swedish Orphan Biovitrum's score of 56 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Swedish Orphan Biovitrum AB (Sobi) reported total carbon emissions of approximately 253,324,000 kg CO2e. This includes 1,097,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 771,000 kg CO2e from Scope 2 emissions, related to purchased electricity, heat, and cooling. The majority of their emissions, about 251,456,000 kg CO2e, fall under Scope 3, which includes indirect emissions from the value chain. Sobi has set ambitious climate commitments, aiming for a 50% reduction in operational greenhouse gas emissions from a 2015 baseline by 2025 for both Scope 1 and Scope 2 emissions. Additionally, they have committed to achieving net-zero emissions for their operational footprint by 2030. Their near-term targets, validated by the Science Based Targets initiative (SBTi), include a 37.8% absolute reduction in combined Scope 1 and 2 emissions by 2029, using 2023 as the base year. Furthermore, Sobi aims for 65% of its suppliers, by spend, to have science-based targets by the same year. Overall, Sobi's emissions data and reduction initiatives reflect a strong commitment to sustainability and climate action within the pharmaceutical and biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 156,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 129,000 | 000,000 | 00,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
Scope 3 | 922,000 | 0,000,000 | 0,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.